00:41:10 Europe / Stockholm

Prenumeration

Filter arrow-icon
Språk arrow-icon
2020-10-01 10:13:00
Ny artikel om CombiGene i Biostock
Biostock sammanfattar de senaste nyheterna från CombiGene och pratar med vd Jan Nilsson om betydelsen av de många milstolparna och den fortsatta planen för epilepsiprojektet CG01.https://www.biostock.se/2020/10/combigene-ar-ytterligare-ett-steg-narmare-kliniska-studier/
2020-10-01 10:13:00
New article about CombiGene in Biostock
Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01.https://www.biostock.se/en/combigene-one-step-closer-to-clinical-trials/
2019-05-27 15:00:00
Nytt nummer av CombiGenes nyhetsbrev ute nu
Läs nyhetsbrevet på svenska via länken nedan. https://issuu.com/pub10/docs/combigene_genevagen_2_2019?e=0 Eller ladda ner bilagan
2019-05-27 15:00:00
New issue of CombiGene´s newsletter Ingenious
Read CombiGene´s newsletter Ingeneious in English https://issuu.com/pub10/docs/combigene_ingeneious_2_2019?e=0 Or download the attachment
2018-12-17 08:41:41
CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ) will be traded on Nasdaq First North Stockholm. The first day of trading is December 19, 2018. The shares and the subscription rights will be traded with unchanged ticker (COMBI) and ISIN-Code (SE0006504593) for the share and (COMBI TO 2) and ISIN-code (SE0011616408) for the subscription rights. ...
2018-12-14 15:53:16
Ingeneious #5 2018, News from CombiGene
Our idea of “Ingeneious” is to keep you updated about the company’s journey and development and to let you know our research findings and successes along the way. Read Ingeneious >>
2018-12-14 13:40:02
CombiGene featured in an article in Nature, one of the world’s leading scientific journals
The latest number of Nature (Vol. 564, Issue 7735, 13 December 2018) features CombiGene’s operations, and the possibilities of using gene therapy to treat epilepsy. Both CombiGene’s scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted. “CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development...
2018-12-11 10:27:40
January 29, Lund Aktiedagen
2018-12-10 15:09:02
April 4, National ATMP Conference 2019, Göteborg
National ATMP Conference 2019, Göteborg Read more: https://gallery.mailchimp.com/fad06aa5114b64b89b04e837f/images/8e9cfe69-062c-4685-a01c-4f48c3f61161.jpg
2018-12-10 15:07:00
April 23-25, Conference Barcelona
Meet CombiGene at the Cell & Gene Meeting on the Med conference April 23-25, 2019 in Barcelona, Spain! Europe’s premier annual conference in the cell and gene therapy sector. The meeting features expert-led panels, in-depth keynote speeches, and presentations by leading publicly traded and privately held companies from around the globe. For more information on the meeting: https://alliancerm.org...
2018-12-10 14:59:40
June 3-6, BIO International Convention
2019 BIO International Convention Venue: Pennsylvania Convention Center, Philadelphia, US One of the worlds biggest life science partnering conference, is an important forum where CombiGene can meet potential partners in a range of disciplines. Read more: https://convention.bio.org/2019/https://convention.bio.org/2019/
2018-12-10 11:08:59
September 10-12, NLSDays, Malmö
NLSDays, Malmö Read more: https://www.nlsdays.com/
2018-11-14 13:18:48
Interim Report January – September 2018
To the Report >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-10-19 16:34:42
CombiGene’s rights issue registered – BTU converted to shares and warrants
CombiGene AB (publ) (”CombiGene” or ”the Company”) concluded a preferential rights issue of units amounting to MSEK 31 on 18 September 2018. The preference issue was subscribed to about MSEK 46, which corresponds to a subscription rate of about 148 percent. The issue has been registered with the Swedish Companies Registration Office and the final date of trade in BTU is 25 October 2018. Th...
2018-10-19 11:29:44
December 4 2018 Professor Merab Kokaia attracts international attention
The scientific founder of CombiGene, Merab Kokaia äs invited to speak at the worlds first forum for epilepsy – The American Epilepsy Society's Annual Meeting. https://meeting.aesnet.org/ The meeting, that will take place on November 30th to December 4th in New Orleans USA, collects the leading representatives for academy, klinical, industrial and representatives for epileptics. The title of Mer...
2018-10-19 11:24:36
September 11–12, 2018 Nordic Life Science Days
Nordic Life Science Days Venue: Stockholm Water Front, Stockholm Nordens största partneringkonferens för Life Science-industrin. The biggest partner conference for the Life Science-industry in the north Read more: www.nlsdays.com "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish vers...
2018-10-19 11:22:51
September 11 2018 Aktiespararna, Stora Aktiedagen
Aktiespararna, Stora Aktiedagen Venue: Operaterrassen, Karl XII:s torg Stockholm. Time: ca 10:50 - 11:20 Read more: https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-1 "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory...
2018-10-19 11:20:18
August 30 2018 FS Markets, Investerardagen
FS Markets, Investmentday Venue: Malmö Börshus, Skeppsbron 2, Malmö. Time: est. 09.30 - 09.55 Read more: www.eventbrite.com/e/inbjudan-investerardagen-malmo-ett-frukost-lunchseminarium-30-augusti-tickets-49215011424?ref=ecount "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish versio...
2018-10-19 10:39:26
CombiGene: Warrants commence trading
In connection with the completed preferential rights issue in CombiGene AB (publ) (”CombiGene” or ”the Company”), subscribers were allotted warrants of series 2018/2019. Trading in warrants on Spotlight Stock Market will commence on 31 October 2018 and the final day of trading in these warrants will be 26 September 2019. Subscription warrants of series 2018/2019 entitle the holder to subsc...
2018-10-01 14:00:27
Clarification of information concerning new issue
The units issued upon the board’s decision on 22 August 2018 consisted of both shares and warrants. The shares were issued upon authorization which the annual general meeting had submitted to the board in advance. Since, at the time of the annual general meeting, there was uncertainty as to how the capital acquisition would be structured, the authorization did not include warrants. The board has...
2018-09-27 13:50:41
CombiGene closer to clinical trials after oversubscribed issue
BioStock interviews CEO Jan Nilsson concerning the issue and the future To interview (in Swedish) >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-09-25 13:55:56
Disclosure notice
CombiGene AB (publ) hereby gives notice that Lars Thunberg’s ownership interest has been reduced in connection with the recently completed preferential rights issue, since he has not utilized his subscription rights in full. The ownership interest has been reduced from about 16.1 percent to about 7.3 percent of the company’s shares and votes. Lars Thunberg’s shareholding in CombiGene AB has ...
2018-09-21 09:43:46
CombiGene’s preference issue, amounting to 31 million kronor, oversubscribed
The subscription period for a preference share issue in CombiGene AB (“CombiGene” or “the Company”) amounting to about MSEK 31 ended on 18 September 2018. The preference issue was subscribed to about MSEK 46, which corresponds to a subscription rate of about 148 percent. The issue will generate about MSEK 31.0 before deductions for issuing expenses. Consequently, the issue guarantees have ...
2018-09-06 15:51:19
Jan Nilsson tell us about the future among other things in an interview with Finwire
In a new interview on September 3 with Finwire.tv the CEO Jan Nilsson talks about the company, market and future plans (Only in swedish) "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to th...
2018-09-05 11:01:31
R&D manager Karin Agerman and CEO Jan Nilsson are interviewed in conjunction with BioStock Live Capital Market Day
Wednesday 29 August a capitalmarket day was arranged in Stockholm with several life sience companies. CombiGene took part with CEO Jan Nilsson and R&D chief Karin Angeman. You can see their conversation with Biostock analytic Linus Flink Elmfors below: (Only in swedish) "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version an...
2018-09-04 11:38:12
"Apparently FDA have a lot of fate in the possibilities of gene-therapy" Interview with Jan Nilsson
"During 2018 CombiGene together with CGT Catapult will drive the process development of our pharmacutical canidate CG01 in order to in 2019 start the regulatory obligatory biodistribution and toxocologystudies. — Jan Nilsson, CEO CombiGene Read the entire interview at Boistock with Jan Nilsson, CEO at CombiGene here: (Only in swedish) https://www.biostock.se/2018/09/combigene-uppenbarligen-har-f...
2018-09-03 13:54:18
Ingeneious #3 2018, News from CombiGene
Our idea of “Ingeneious” is to keep you updated about the company’s journey and development and to let you know our research findings and successes along the way. Read Ingeneious >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of re...
2018-09-03 10:30:41
Kapitalmarknadsdag in Stockholm with several leading life science companies in which CombiGene also participated (In swedish)
Onsdagen 29 augusti arrangerade Biostock en kapitalmarknadsdag i Stockholm med flera ledande life science-bolag där också CombiGene deltog med VD Jan Nilsson och FoU chefen Karin Agerman
2018-08-24 16:13:07
CombiGene publishes the prospectus for the rights issue
CombiGene AB (publ) (”CombiGene” or ”the Company”) publishes this prospectus pursuant to a resolution by the board of CombiGene AB on 22 August 2018 to introduce a preference issue of units (”the Issue”). Full subscription of the offer will generate about MSEK 31.0 before deductions for issuing expenses. Read more >> "This is an English translation of the Swedish website; if there is a...
2018-08-22 15:42:10
CombiGene announces a 75-percent guaranteed preference issue of units amounting to 31 million kronor
The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal for a preferential rights issue of shares and warrants (”the Offer” or ”the Rights Issue”). Full subscription of the offer will generate about MSEK 31 before deductions for issuing expenses. Read more >> "This is an English translation of the Swedish website; if there is any inconsi...
2018-08-22 09:15:24
Interim Report January - june 2018
Interim Report >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-06-14 14:18:08
New research data provide additional support for CombiGene’s gene therapy for difficult-to-treat epilepsy
In epilepsy patients, drug-resistant seizures often occur in one of the temporal lobes. The problematic area can, in some patients, be removed surgically, resulting in a positive treatment outcome for the patient. Read more >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version s...
2018-06-12 16:03:46
CombiGene participated in a positive meeting with the European Medicines Agency
All development of new and unique therapies for humans and animals requires close cooperation with the public agencies that make the final decision on product approval. Read more >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulato...
2018-06-04 15:13:38
Ingeneious #2 2018, News from CombiGene
Our idea of “Ingeneious” is to keep you updated about the company’s journey and development and to let you know our research findings and successes along the way. Read Ingeneious >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of re...
2018-05-03 13:18:13
Interim Report January-March 2018
Read the report>> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-05-02 11:02:43
Annual Report 2017
To the Annual Report >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-04-09 15:54:13
CombiGene: New issue registered
CombiGene AB realized a preference share issue in February 2018. The issue raised 2.3 million kronor before issuing expenses. Read more >>
2018-03-29 15:40:29
Notice of Annual General Meeting of shareholders in CombiGene AB (publ)
Shareholders in CombiGene AB (publ) are hereby invited to attend the Annual General Meeting at 2.30 p.m. on 3 May 2018 at Tellus, Medicon Village, Scheelevägen 2, Lund. Registration for the meeting will commence one half-hour before the meeting and will end when the meeting opens. Read more >>
2018-03-13 14:44:27
CombiGene: Now we’re strengthening our management team with the addition of Karin Agerman as Chief Research & Development Officer.
During 2018 CombiGene is entering a decisive phase with focus on development of a manufacturing method for our candidate drug, CG01, and continued intensive business development. This will demand a good measure of professionalism and expertise, as well as energy and enthusiasm. Read more >> -->
2018-03-05 14:55:54
CombiGene: CombiGene’s issue was subscribed to 22.5 percent
The preference share issue, realized during the period 12 February – 28 February 2018, was subscribed to 22.5 percent, 79 percent of which was subscribed with subscription rights. The issue raised 2.3 million kronor in issue capital before issuing expenses amounting to about MSEK 0.3. Contract notes will be sent to those who subscribed for shares without preferential rights during the coming wee...
2018-02-22 14:50:37
All of CombiGene’s board and management will subscribe for shares in the new issue.
CombiGene had a very intensive year in 2017, with three successful preclinical studies. Thanks to the positive results from these studies, CombiGene is now preparing for the next important step on our path to an approved drug via our collaboration with British CGT Catapult for development of a method for manufacturing our candidate drug, CG01. To finance this development, CombiGene is now carrying...
2018-02-19 14:13:37
Final data from long-term study of CombiGene’s epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.
Final data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects. The study has demonstrated that CG01 reduces the frequency and duration of epileptic seizures in treatment-responsive animals. A couple of the animals were completely free of seizures after being treated. No side effects have been obs...
2018-02-12 14:22:01
CombiGene AB publishes memorandum
CombiGene AB publishes this memorandum pursuant to a resolution by the board of CombiGene AB on 22 January to introduce a preference share issue which was authorized by the Annual General Meeting on 9 May 2017. The new issue is a preference share issue, whereby existing shareholders have preferential right to subscribe for new shares. The issue is also open to other investors. Full subscription of...
2018-01-31 15:18:41
CombiGene establishes UK subsidiary to secure close and effective collaboration with Cell and Gene Therapy Catapult
Read more >>
2018-01-29 11:28:02
Year-end statement January-December 2017
Read Statement >> "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
2018-01-24 15:01:38
CombiGene participates in Life Science Day, Wednesday 7 March
Life Science Day for companies listed on Aktietorget will take place on 7 March, from 8.30 a.m. to 6 p.m., at the Wallenberg Conference Center, Sahlgrenska University Hospital, in Gothenburg. Life Science 2017 >>
2018-01-23 15:04:38
CombiGene AB (publ) presents the year-end statement for 2017 at an earlier date than planned
The Board of Directors of CombiGene AB has decided to present the year-end statement for 2017 at an earlier date than planned, since the statement has been prepared sooner than expected. The new publication date is 29 January, 2018
2018-01-22 15:08:56
CombiGene’s board approves preferential rights issue
The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal for a preferential rights issue amounting to MSEK 10.2 for existing shareholders (”the Offer” or ”the Rights Issue”). The capital raised via the offer will be used to fund the company’s development of a manufacturing process for CombiGene’s candidate drug, CG01, in collaboration...